News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Cumbo Alexander
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/05/2022 |
4
| Cumbo Alexander (President and CEO) has filed a Form 4 on Solid Biosciences Inc.|
Txns:
| Granted 584 shares
@ $0
Granted 228,900 options to buy
@ $6.77, valued at
$1.5M
Granted 114,449 restricted stock units
@ $0 |
|
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/03/2020 |
4
| Cumbo Alexander (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 15,000 options to buy
@ $19.88, valued at
$298.2k
Disposed/sold 25,000 options to buy
@ $12.99, valued at
$324.8k
|
|
| 02/28/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/17/2019 |
4
| Cumbo Alexander (EVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Sold 32,706 shares
@ $125.5, valued at
$4.1M
Sold 9,294 shares
@ $125.5, valued at
$1.2M
Exercised 2,727 options to buy
@ $13.71, valued at
$37.4k
Exercised 3,895 options to buy
@ $13.71, valued at
$53.4k
Exercised 26,084 options to buy
@ $26.24, valued at
$684.4k
|
|
| 06/13/2019 |
4
| Cumbo Alexander (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options to buy
@ $19.88, valued at
$298.2k
|
|
| 03/29/2019 |
4
| Cumbo Alexander (EVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 4,876 shares
@ $0
Paid exercise price by delivering 2,165 shares
@ $118.68, valued at
$256.9k
|
|
| 03/04/2019 |
4
| Cumbo Alexander (EVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Disposed/sold 3,375 shares
@ $0
Granted 45,000 options to buy
@ $145.48, valued at
$6.5M
|
|
| 02/01/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/15/2018 |
4
| Cumbo Alexander (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $12.99, valued at
$324.8k
|
|
| 08/08/2018 |
4
| Cumbo Alexander (SVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 6,000 shares
@ $121.02, valued at
$726.1k
|
|
| 07/11/2018 |
4
| Cumbo Alexander (SVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Sold 11,924 shares
@ $137.32, valued at
$1.6M
Sold 9,944 shares
@ $137.32, valued at
$1.4M
Sold 11,914 shares
@ $137.32, valued at
$1.6M
Exercised 11,924 options to buy
@ $13.71, valued at
$163.5k
Exercised 9,944 options to buy
@ $13.71, valued at
$136.3k
Exercised 11,914 options to buy
@ $13.9, valued at
$165.6k
|
|
| 05/24/2018 |
4
| Cumbo Alexander (SVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,435 shares
@ $89.22, valued at
$128k
Exercised 4,876 restricted stock units
@ $0 |
|
| 03/16/2018 |
4
| Cumbo Alexander (SVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 40 shares
@ $81.22, valued at
$3.2k
Paid exercise price by delivering 9 shares
@ $81.22, valued at
$731
Paid exercise price by delivering 142 shares
@ $81.22, valued at
$11.5k
Paid exercise price by delivering 442 shares
@ $81.22, valued at
$35.9k
Exercised 241 options to buy
@ $13.71, valued at
$3.3k
Exercised 54 options to buy
@ $13.71, valued at
$740.3
Exercised 835 options to buy
@ $13.9, valued at
$11.6k
Exercised 1,370 options to buy
@ $26.24, valued at
$35.9k
|
|
| 03/07/2018 |
4
| Cumbo Alexander (SVP, Chief Commercial Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 70,000 options to buy
@ $71.45, valued at
$5M
|
|
| 08/07/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/14/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|